PL3439645T3 - Stosowanie tamoksyfenu w leczeniu mukowiscydozy u pacjentów płci innej niż żeńska - Google Patents

Stosowanie tamoksyfenu w leczeniu mukowiscydozy u pacjentów płci innej niż żeńska

Info

Publication number
PL3439645T3
PL3439645T3 PL17715154.5T PL17715154T PL3439645T3 PL 3439645 T3 PL3439645 T3 PL 3439645T3 PL 17715154 T PL17715154 T PL 17715154T PL 3439645 T3 PL3439645 T3 PL 3439645T3
Authority
PL
Poland
Prior art keywords
tamoxifen
treatment
cystic fibrosis
female patients
patients
Prior art date
Application number
PL17715154.5T
Other languages
English (en)
Inventor
Giorgio BALDUZZI
Original Assignee
Gb Pharma S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gb Pharma S.R.L. filed Critical Gb Pharma S.R.L.
Publication of PL3439645T3 publication Critical patent/PL3439645T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17715154.5T 2016-04-05 2017-04-03 Stosowanie tamoksyfenu w leczeniu mukowiscydozy u pacjentów płci innej niż żeńska PL3439645T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUA2016A002292A ITUA20162292A1 (it) 2016-04-05 2016-04-05 Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti di entrambi i sessi
PCT/EP2017/057895 WO2017174529A1 (en) 2016-04-05 2017-04-03 Use of tamoxifen for the treatment of cystic fibrosis in patients of both sexes

Publications (1)

Publication Number Publication Date
PL3439645T3 true PL3439645T3 (pl) 2023-08-21

Family

ID=56551460

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17715154.5T PL3439645T3 (pl) 2016-04-05 2017-04-03 Stosowanie tamoksyfenu w leczeniu mukowiscydozy u pacjentów płci innej niż żeńska

Country Status (14)

Country Link
US (1) US11191738B2 (pl)
EP (1) EP3439645B1 (pl)
JP (1) JP2019510791A (pl)
CN (1) CN109310652A (pl)
CA (1) CA3018024A1 (pl)
EA (1) EA036682B1 (pl)
ES (1) ES2951263T3 (pl)
HR (1) HRP20231197T1 (pl)
HU (1) HUE064521T2 (pl)
IT (1) ITUA20162292A1 (pl)
PL (1) PL3439645T3 (pl)
RS (1) RS64640B1 (pl)
SM (1) SMT202300246T1 (pl)
WO (1) WO2017174529A1 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE214269T1 (de) * 1997-06-27 2002-03-15 Akzo Nobel Nv Oral anzuwendende flüssige arzneilösung
WO2009105234A2 (en) * 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
WO2012134965A1 (en) 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases

Also Published As

Publication number Publication date
EA201891911A1 (ru) 2019-04-30
EP3439645B1 (en) 2023-07-05
SMT202300246T1 (it) 2023-11-13
WO2017174529A1 (en) 2017-10-12
HRP20231197T1 (hr) 2024-01-19
ITUA20162292A1 (it) 2017-10-05
EP3439645A1 (en) 2019-02-13
US11191738B2 (en) 2021-12-07
EA036682B1 (ru) 2020-12-08
JP2019510791A (ja) 2019-04-18
US20200297667A1 (en) 2020-09-24
ES2951263T3 (es) 2023-10-19
RS64640B1 (sr) 2023-10-31
CA3018024A1 (en) 2017-10-12
EP3439645C0 (en) 2023-07-05
CN109310652A (zh) 2019-02-05
HUE064521T2 (hu) 2024-03-28

Similar Documents

Publication Publication Date Title
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL250960A0 (en) Combined treatment of sinecriviroc for the treatment of leprosy
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
GB2538923B (en) A therapeutic agent for use in the treatment of infections
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
ZA201906473B (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
IL246855A0 (en) Materials for use in the treatment of retinitis
IL273863B1 (en) Hemorrhoid treatment device
PL3320901T3 (pl) Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc
IL247882A0 (en) The composition for use in the treatment of pain associated with an intervertebral disc
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
GB201600637D0 (en) Therapeutic treatment methods and apparatus for use therein
SMT202300246T1 (it) Uso del tamoxifene per il trattamento della fibrosi cistica in pazienti non femminili
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido